Delving into the Latest Updates on Admedus Vaccines Pty Ltd. with Synapse

Overview

Tags

Otorhinolaryngologic Diseases

Neoplasms

Mouth and Tooth Diseases

DNA vaccine

Therapeutic vaccine

Prophylactic vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

DNA vaccine	2
Therapeutic vaccine	1
Prophylactic vaccine	1

We have previously shown that a novel DNA vaccine technology of codon optimization and the addition of ubiquitin sequences enhanced immunogenicity of a herpes simplex virus 2 polynucleotide vaccine in mice, and induced cell-mediated immunity when administered in humans at relatively low doses of naked DNA. We here show that a new polynucleotide vaccine using the same technology and encoding a fusion protein of the E6 and E7 oncogenes of high-risk human papillomavirus type 16 (HPV16) is immunogenic in mice. This vaccine induces long-lasting humoral and cell-mediated immunity and protects mice from establishment of HPV16-E7-expressing tumors. In addition, it suppresses growth of readily established tumors and shows enhanced efficacy when combined with immune checkpoint blockade targeted at PD-L1. This vaccine also facilitates rejection of HPV16-E7-expressing skin grafts that demonstrate epidermal hyperplasia with characteristics of cervical and vulvar intraepithelial neoplasia. Clinical studies evaluating the efficacy of this vaccine in patients with HPV16+ premalignancies are planned.

01 Dec 2016·Human Vaccines & ImmunotherapeuticsQ3 · MEDICINE

An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1

Q3 · MEDICINE

Article

Author: Dutton, Julie L. ; Griffin, Paul ; Li, Bo ; Woo, Wai-Ping ; Finlayson, Neil ; Frazer, Ian H. ; Chandra, Janin ; Xu, Yan

This paper describes a single site, open-label Phase I clinical trial evaluating the safety, tolerability and immunogenicity in healthy volunteers of a herpes simplex polynucleotide vaccine that has previously been shown to enhance immunogenicity and protect against lethal herpes simplex virus type 2 (HSV-2) challenge in mice. Five escalating doses of the vaccine, COR-1, were given by intradermal injection to HSV-1 and 2 seronegative healthy individuals. COR-1 was found to be safe and well-tolerated; the only vaccine-related adverse events were mild. While vaccine-induced antibody responses were not detectable, cell-mediated immune responses to HSV-specific peptide groups were identified in 19 of the 20 subjects who completed the study, and local inflammation at the immunisation site was observed. This study indicates COR-1 has potential to be used as a therapeutic vaccine for HSV-2 infection.

PLOS ONEQ3 · CROSS-FIELD

Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial

Q3 · CROSS-FIELD

ArticleOA

Author: Druce, Julian ; Griffin, Paul ; Finlayson, Neil ; Laing, Kerry J ; Li, Bo ; Woo, Wai-Ping ; Dutton, Julie L ; Koelle, David M ; Frazer, Ian H ; Chandra, Janin ; Xu, Yan ; Kinrade, Sally

BACKGROUNDGenital herpes simplex infection affects more than 500 million people worldwide. We have previously shown that COR-1, a therapeutic HSV-2 polynucleotide vaccine candidate, is safe and well tolerated in healthy subjects.OBJECTIVEHere, we present a single center double-blind placebo-controlled, randomized phase I/IIa trial of COR-1 in HSV-2 positive subjects in which we assessed safety and tolerability as primary endpoints, and immunogenicity and therapeutic efficacy as exploratory endpoints.METHODSForty-four HSV-2+ subjects confirmed by positive serology or pathology, and positive qPCR during baseline shedding, with a recurrent genital HSV-2 history of at least 12 months including three to nine reported lesions in 12 months prior to screening, aged 18 to 50 years females and males with given written informed consent, were randomized into two groups. Three immunizations at 4-week intervals and one booster immunization at 6 months, each of 1 mg COR-1 DNA or placebo, were administered intradermally as two injections of 500 μg each to either one forearm or both forearms.RESULTSNo serious adverse events, life-threatening events or deaths occurred throughout the study. As expected, HSV-2 infected subjects displayed gD2-specific antibody titers prior to immunization. COR-1 was associated with a reduction in viral shedding after booster administration compared with baseline.CONCLUSIONSThis study confirms the previously demonstrated safety of COR-1 in humans and indicates a potential for use of COR-1 as a therapy to reduce viral shedding in HSV-2 infected subjects.

100 Deals associated with Admedus Vaccines Pty Ltd.

Login to view more data

100 Translational Medicine associated with Admedus Vaccines Pty Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Phase 2 Clinical

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

HSV-2 vaccine (University of Queensland)	Herpesviridae Infections More	Phase 2
AMV-002	Oropharyngeal Neoplasms More	Phase 1
DNA vaccines(Admedus Immunotherapies)	Epstein-Barr Virus Infections More	Pending
Epstein Barr Virus vaccine(Admedus Immunotherapies)	Epstein-Barr Virus Infections More	Pending